GTx, Inc. (GTXI) Insider Sells $35,009.70 in Stock

GTx, Inc. (NASDAQ:GTXI) insider Jason T. Shackelford sold 3,090 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $11.33, for a total transaction of $35,009.70. Following the completion of the sale, the insider now owns 31,111 shares in the company, valued at approximately $352,487.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

GTx, Inc. (NASDAQ:GTXI) opened at $11.56 on Friday. The firm has a market cap of $240.19, a price-to-earnings ratio of -6.61 and a beta of 1.77. GTx, Inc. has a one year low of $2.73 and a one year high of $13.35.

GTX (NASDAQ:GTXI) last issued its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25). analysts expect that GTx, Inc. will post -1.61 earnings per share for the current year.

GTXI has been the topic of several research reports. Stifel Nicolaus initiated coverage on shares of GTX in a report on Thursday, November 9th. They issued a “buy” rating on the stock. Robert W. Baird initiated coverage on shares of GTX in a report on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 target price on the stock. Finally, Zacks Investment Research cut shares of GTX from a “hold” rating to a “sell” rating in a report on Wednesday.

Several institutional investors have recently modified their holdings of GTXI. Bank of New York Mellon Corp purchased a new position in shares of GTX during the 2nd quarter worth $124,000. Abingworth LLP bought a new stake in shares of GTX during the 3rd quarter valued at $2,781,000. Finally, Caxton Corp bought a new stake in shares of GTX during the 3rd quarter valued at $531,000. Institutional investors and hedge funds own 11.57% of the company’s stock.

TRADEMARK VIOLATION WARNING: “GTx, Inc. (GTXI) Insider Sells $35,009.70 in Stock” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at

GTX Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with's FREE daily email newsletter.

Leave a Reply